Phase 2
Completed N=41
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
Source: ClinicalTrials.gov NCT03034356 ↗Enrolled (actual)
41
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcomePrimary: Neurocognitive Function — 73.68; 74.04; 3.36; 3.96 Total score
Summary
This study plans to learn more about the effects of levetiracetam (LEV) on brain activity and cognition in schizophrenia and schizoaffective disorder. Levetiracetam is an anti-seizure drug, also called an anticonvulsant.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Neurocognitive Function |
73.68; 74.04; 3.36; 3.96 | — |
| SECONDARY Resting-state Neuronal Response |
— | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of schizophrenia or schizoaffective disorder
- Good general health
- Normal vital signs (blood pressure, pulse, respiration)
Exclusion Criteria
- Substance abuse
- Significant neurological disorders
- Significant head trauma/injury
- Pregnancy
- MRI-specific exclusion criteria, e.g.,:
- claustrophobia
- weight>400 lbs
- metal in the body
Data sourced from ClinicalTrials.gov (NCT03034356). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.